Ceraxon (Citicoline) oral solution 100 mg/ml, 10ml x 10 sachets — Made in Spain — Free Delivery

Pharmacodynamics. Citicoline stimulates the biosynthesis of structural phospholipids of neuronal membranes, which is confirmed by the data of magnetic resonance spectroscopy. due to this mechanism of action, citicoline improves the functioning of such membrane mechanisms as the work of ion-exchange pumps and receptors, the modulation of which is necessary for the normal conduction of nerve impulses.

Due to the stabilizing effect on the membrane of neurons, citicoline exhibits decongestant properties that help to reduce cerebral edema.

Experimental studies have shown that citicoline inhibits the activation of certain phospholipases (A1, A2, C and D), reduces the formation of free radicals, prevents the destruction of membrane systems, and preserves antioxidant defense systems such as glutathione.

Citicoline preserves the energy storage of neurons, inhibits apoptosis and stimulates the synthesis of acetylcholine.

It has been experimentally proven that citicoline also has a prophylactic neuroprotective effect in focal cerebral ischemia.

Clinical studies have shown that citicoline significantly increases functional recovery in patients with acute ischemic cerebrovascular accident, which coincides with a slowdown in the increase in the volume of ischemic brain damage according to neuroimaging data.

In patients with traumatic brain injury, citicoline accelerates recovery and reduces the duration and intensity of post-traumatic stress disorder.

Citicoline increases the level of attention and consciousness, reduces the severity of cognitive and neurological disorders associated with cerebral ischemia, helps to reduce the manifestations of amnesia.

Pharmacokinetics. Citicoline is almost completely absorbed when taken orally. After administration of the preparation, there is a significant increase in the level of choline in the blood plasma.

The preparation is metabolized in the intestine and liver to form choline and cytidine.

After administration, citicoline is widely distributed in the structures of the brain with the rapid incorporation of the choline fraction into structural phospholipids and cytidine fractions into cytidine nucleotides and nucleic acids. In the brain, citicoline is incorporated into the cellular, cytoplasmic and mitochondrial membranes, integrating into the structure of the phospholipid fraction.

Only a small amount of the dose is detected in urine and feces (less than 3%). About 12% is excreted through the CO2 of the exhaled air. During the excretion of the preparation in the urine, two phases are distinguished: the first phase - within 36 hours, in which the rate of excretion decreases rapidly, and the second phase - in which the rate of excretion decreases much more slowly. The same phasicity is observed when excreted through the respiratory tract. The rate of CO2 elimination decreases rapidly, for about 15 hours, then it decreases much more slowly.

Stroke, acute phase of cerebrovascular accidents and treatment of complications and consequences of cerebrovascular accidents.

Traumatic brain injury and its neurological consequences.

Cognitive and behavioral impairments due to chronic vascular and degenerative cerebral disorders.

For oral administration. The recommended dose of the preparation Ceraxon, solution for oral administration in vials, for adults is from 500 mg (5 ml) to 2000 mg (20 ml) per day, which should be divided into 2-3 doses, depending on the severity of symptoms.

The preparation should be taken with a dosing syringe according to the following scheme:

before use, the syringe dosing plunger should be completely squeezed in;

pull back the plunger and dial the required dose, taking into account that the amount of liquid in the syringe must correspond to the prescribed dose;

the preparation is taken directly or diluted with half a glass of water (120 ml), regardless of food intake.

The dosing syringe should be flushed with water after each use.

The recommended dose of the preparation Cerakson, solution for oral administration in a sachet, is 1–2 sachets (10–20 ml) per day, depending on the severity of the course of the disease. The preparation should be taken directly with a sachet or diluted with half a glass of water (120 ml), regardless of the meal.

Doses of the preparation and the duration of treatment depend on the severity of the brain lesions and are set individually.

Elderly patients do not need dose adjustment.

Hypersensitivity to citicoline or other components of the preparation.

Increased tone of the parasympathetic nervous system.

Adverse reactions occur very rarely (1/10 000), including isolated cases.

From the side of the central and peripheral nervous system: severe headache, vertigo, hallucinations.

From the side of the cardiovascular system: arterial hypertension, arterial hypotension, tachycardia.

From the respiratory system: shortness of breath.

From the digestive tract: nausea, vomiting, diarrhea.

From the immune system: allergic reactions, including rash, hyperemia, exanthema, urticaria, purpura, pruritus, angioedema, anaphylactic shock.